Tackling APOE's structural challenges via in silico modeling in the era of neural networks: Can AlphaFold II help circumvent the problem of lacking full-length protein structure?

Journal: Archives of biochemistry and biophysics
PMID:

Abstract

The APOE gene, encoding apolipoprotein E, is a predictor of longevity and age-related diseases. Despite numerous genetic studies, the data on molecular mechanisms by which apolipoprotein E affects the human phenotype remain incomplete due to the structural properties of the protein. Recently, a number of studies have used in silico drug discovery techniques based on protein-ligand docking, further highlighting the issue of lacking 3D structure of apolipoprotein E. Using molecular dynamics simulation, we found that AlphaFold II models of apolipoprotein E conformationally significantly differ both from the only available NMR structure, 2L7B, and structures obtained through circular dichroism spectroscopy: the ε4 isoform lacks the salt bridge between R61 and E255, while the ε2 and ε3 isoforms have extensive networks of interdomain interactions. Our findings challenge the benefits of using AlphaFold II for obtaining starting conformations for molecular docking.

Authors

  • A A Mamchur
    Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, bld.10/1, Pogodinskaya Str., Moscow, 119121, Russia; The Faculty of Biology of Lomonosov Moscow State University, Leninskie Gory, 1, Moscow, 119991, Russia. Electronic address: amamchur@cspfmba.ru.
  • M V Ivanov
    Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, bld.10/1, Pogodinskaya Str., Moscow, 119121, Russia.
  • L R Matkava
    Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, bld.10/1, Pogodinskaya Str., Moscow, 119121, Russia.
  • V S Yudin
    Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, bld.10/1, Pogodinskaya Str., Moscow, 119121, Russia.
  • A A Keskinov
    Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, bld.10/1, Pogodinskaya Str., Moscow, 119121, Russia.
  • S M Yudin
    Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, bld.10/1, Pogodinskaya Str., Moscow, 119121, Russia.
  • D A Kashtanova
    Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, bld.10/1, Pogodinskaya Str., Moscow, 119121, Russia.